Soultan Al-Halifa
Director, Research & Development, Biopharmaceutical Chemistry Feldan Therapeutics
Soultan Al-Halifa is an accomplished Director of R&D in Biopharmaceutical Chemistry at Feldan Therapeutics, Quebec, with a strong background in molecular engineering, organic, mineral, and industrial chemistry. Soultan leads multidisciplinary teams to advance drug delivery platforms, translates R&D projects into clinical applications, and manages intellectual property creation. Previous roles include Project Manager and Research Specialist II at Feldan, where Soultan assembled and led scientific teams, oversaw analytical studies, and contributed to patent development. Earlier, Soultan held postdoctoral research positions at the University of Quebec at Montreal and KU Leuven, focusing on peptide-based nanomaterials, nanovaccines, and biomaterials for drug delivery and tissue engineering. Soultan’s expertise spans laboratory setup, chemical synthesis, team supervision, and collaboration with academic groups, supported by a Ph.D. from the University of Montpellier and multiple scientific publications and patents.
Seminars
- Where do LNPs begin to show limitations for extrahepatic delivery and which emerging delivery vehicles offer the most realistic advantages?
- How do alternative delivery platforms compare in terms of manufacturability, scalability, safety, and regulatory readiness when moving towards the clinic?
- Which delivery challenges, from immunogenicity to targeting specificity, are best addressed by exploring non-LNP platforms, and where do LNPs remain the most practical solution?
- Incorporating peptides in LNPs had minimal impact on particle properties and showed improved intracellular delivery of mRNA
- The presence of peptides in LNPs did not change particle biodistribution in vivo
- Peptide-LNPs showed higher mRNA delivery in most organs vs LNP control
